Emerging from the COVID-19 pandemic, pharmaceutical and biotech leaders face acute challenges related to patient recruitment, talent shortages, and the increasing complexity of clinical trials.
The report, R&D Trends in Pharma and Biotech, reflects today’s challenges and opportunities in bringing new therapies to market, as disclosed by more than 150 decision-making leaders at pharmaceutical and biotech companies around the world. Conducted by pharmaceutical market research firm Industry Standard Research (ISR), the survey asked respondents to consider the therapies in their pipelines, barriers to drug development, latest innovations in use, and the lingering effects and lessons of the COVID-19 pandemic.
Read more about the report and how to download it here.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.